AMIODARONE OMEGA SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

AMIODARONE HYDROCHLORIDE

Доступна с:

OMEGA LABORATORIES LIMITED

код АТС:

C01BD01

ИНН (Международная Имя):

AMIODARONE

дозировка:

50MG

Фармацевтическая форма:

SOLUTION

состав:

AMIODARONE HYDROCHLORIDE 50MG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

CLASS III ANTIARRYTHMICS

Обзор продуктов:

Active ingredient group (AIG) number: 0118593002; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2004-04-05

Характеристики продукта

_Amiodarone Omega _
_Page 1 of 59 _
PRODUCT MONOGRAPH PR
AMIODARONE OMEGA
Amiodarone hydrochloride for injection
House Standard
Vials: 50 mg/mL
Antiarrhythmic Agent
Omega Laboratories Limited.
Date of Revision: June 4, 2018
11 177 Hamon
Montreal, Quebec
H3M 3E4
Control Number: 213232
_Amiodarone Omega _
_Page 2 of 59 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................
15
DRUG INTERACTIONS
.......................................................................................................................
18
DOSAGE AND ADMINISTRATION
...................................................................................................
22
OVERDOSAGE
.....................................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
27
STORAGE AND STABILITY
...............................................................................................................
30
SPECIAL HANDLING INSTRUCTIONS
.............................................................................................
30
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................... 30
PART II: SCIENT